Trial · NCT04273061
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061, Phase 2, Recruiting, British Columbia Cancer Agency
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity. Trials, record NCT04273061. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04273061
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
- NCT number
- NCT04273061
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- British Columbia Cancer Agency
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
- Interventions
- Atezolizumab
- First posted
- 2020-02-17
- Last updated
- 2026-09-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) for the study cohort, as defined by RECIST 1.1 | From the date of the screening scan (within 28 days of first dose) until the date of confirmed progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | The proportion of participants in the study cohort who have a complete response (CR) or partial response (PR) to treatment, as defined by RECIST 1.1. |
| Secondary | Progression-free survival (PFS) for the study cohort from the initiation of atezolizumab | From the date of first dose until the date of confirmed progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | The length of time from the first dose of atezolizumab until participants in the study cohort have progressive disease (PD), as defined by RECIST 1.1. |
| Secondary | Clinical benefit rate (CBR) for the study cohort at the 18-week follow-up scan | From the date of the screening scan (within 28 days of first dose) until the date of the 18-week follow-up scan. | The percentage of participants in the study cohort who have a complete response (CR), partial response (PR), or stable disease (SD) response to treatment, as defined by RECIST 1.1, at the 18-week follow-up scan. |
| Secondary | Overall survival (OS) for the study cohort from the initiation of atezolizumab | From the date of first dose until the date of death, assessed up to 54 months. | The length of time from the initiation of atezolizumab that participants in the study cohort survive. |
| Secondary | Quality-adjusted survival for the study cohort from the initiation of atezolizumab | From the date of first dose until the treatment discontinuation visit (within 30 days of last dose), withdrawal, or date of death, whichever comes first, assessed up to 54 months. | Survival time (from the initiation of atezolizumab) multiplied by quality of life. Participants' responses to health-related quality of life questions on the EQ-5D-3L questionnaire will be converted to utility weights using existing conversion scales that are based on patient and public valuations of the health states described by the EQ-5D-3L questionnaire. |
| Secondary | Duration of response (DoR) for the study cohort | From the date of the scan that shows the first response to treatment until the date of progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | The length of time from the first response to treatment (CR or PR) until participants in the study cohort have progressive disease (PD), as defined by RECIST 1.1. |
| Other | Putative markers of sensitivity to atezolizumab for the study cohort | From the date of screening sample collection until the date of progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | From blood and tissue samples collected throughout the study, identify putative markers of sensitivity to atezolizumab based on the response to treatment of the participants in the study cohort. |
| Other | Putative primary and secondary resistance markers to atezolizumab in the study cohort | From the date of screening sample collection until the date of progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | From blood and tissue samples collected throughout the study, identify putative primary and secondary resistance markers to atezolizumab based on the response to treatment of the participants in the study cohort. |
| Other | Putative germline predictors of adverse events or toxicities of interest in the study cohort | From the date of screening sample collection until the date of progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | From blood and tissue samples collected throughout the study, identify putative germline predictors of adverse events or toxicities of interest to atezolizumab based on the response to treatment of the participants in the study cohort. |
| Other | Compare the utility of iRECIST for response assessment to RECIST 1.1 in the study cohort | From the date of the screening scan (within 28 days of first dose) until the date of progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. | Participant response to treatment as per RECIST 1.1. compared to the response to treatment as per the modified response evaluation criteria in solid tumours for immunotherapy trials (iRECIST) from screening until progression in the study cohort. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers39
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04273061
GET https://conductscience.org/api/trials/v1/NCT04273061/papers?page=2